85 related articles for article (PubMed ID: 2340200)
1. C-terminal fragments of gp120 and synthetic peptides from five HTLV-III strains: prevalence of antibodies to the HTLV-III-MN isolate in infected individuals.
Devash Y; Matthews TJ; Drummond JE; Javaherian K; Waters DJ; Arthur LO; Blattner WA; Rusche JR
AIDS Res Hum Retroviruses; 1990 Mar; 6(3):307-16. PubMed ID: 2340200
[TBL] [Abstract][Full Text] [Related]
2. Polyvalent human immunodeficiency virus synthetic immunogen comprised of envelope gp120 T helper cell sites and B cell neutralization epitopes.
Palker TJ; Matthews TJ; Langlois A; Tanner ME; Martin ME; Scearce RM; Kim JE; Berzofsky JA; Bolognesi DP; Haynes BF
J Immunol; 1989 May; 142(10):3612-9. PubMed ID: 2469721
[TBL] [Abstract][Full Text] [Related]
3. High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1MN in sera from Africa and the Americas.
Carrow EW; Vujcic LK; Glass WL; Seamon KB; Rastogi SC; Hendry RM; Boulos R; Nzila N; Quinnan GV
AIDS Res Hum Retroviruses; 1991 Oct; 7(10):831-8. PubMed ID: 1720630
[TBL] [Abstract][Full Text] [Related]
4. Correlation between anti-V3 peptide and neutralizing antibodies in plasma from HIV-1 infected individuals resident in Brazil.
Bongertz V; Morgado MG; Galvão-Castro B; Wigzell H; Hendry RM
Mem Inst Oswaldo Cruz; 1994; 89(1):113-4. PubMed ID: 7823807
[TBL] [Abstract][Full Text] [Related]
5. Immunodominant B-cell clones responsive to an HIV-1 neutralization and cell fusion inhibition epitope in chimpanzee-to-chimpanzee passages of HTLV-IIIB and LAV-1.
Goudsmit J; Bakker M; Smit L
Res Virol; 1989; 140(5):405-18. PubMed ID: 2479965
[TBL] [Abstract][Full Text] [Related]
6. Fine analysis of immunoreactivity of V3 peptides: antibodies specific for V3 domain of laboratory HIV type 1 strains recognize multiple V3 sequences synthesized from field HIV type 1 isolates.
Boudet F; Lasarte JJ; Sarobe P; Borras-Cuesta F; Theze J
AIDS Res Hum Retroviruses; 1996 Dec; 12(18):1671-9. PubMed ID: 8959242
[TBL] [Abstract][Full Text] [Related]
7. The use of synthetic peptides in the diagnosis of HIV infections.
Petrov RV; Khaitov RM; Sidorovich IG; Pavlikov SP; Nikolaeva IA; Ivachenko ME; Andreev SM; Sklyarov LYu
Biomed Sci; 1990 Mar; 1(3):239-44. PubMed ID: 2103826
[TBL] [Abstract][Full Text] [Related]
8. Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees.
Goudsmit J; Debouck C; Meloen RH; Smit L; Bakker M; Asher DM; Wolff AV; Gibbs CJ; Gajdusek DC
Proc Natl Acad Sci U S A; 1988 Jun; 85(12):4478-82. PubMed ID: 2454471
[TBL] [Abstract][Full Text] [Related]
9. Antibodies to V3 loop peptides derived from chimpanzee lentiviruses and the divergent HIV-1ANT-70 isolate in human sera from different geographic regions.
Peeters M; Nkengasong J; Willems B; Karita E; Delaporte E; Van den Haesevelde M; Piot P; van der Groen G
AIDS; 1994 Dec; 8(12):1657-61. PubMed ID: 7888113
[TBL] [Abstract][Full Text] [Related]
10. Correlation between seroreactivity to HIV-1 V3 loop peptides and male-to-female heterosexual transmission.
Fiore JR; Jansson M; Scarlatti G; Angarano G; Caputo SL; Buccoliero G; Rossi P; Fenyö EM; Pastore G
AIDS; 1993 Jan; 7(1):29-31. PubMed ID: 7680206
[TBL] [Abstract][Full Text] [Related]
11. Antisera raised against the second variable region of the external envelope glycoprotein of human immunodeficiency virus type 1 cross-neutralize and show an increased neutralization index when they act together with antisera to the V3 neutralization epitope.
Davis D; Stephens DM; Carne CA; Lachmann PJ
J Gen Virol; 1993 Dec; 74 ( Pt 12)():2609-17. PubMed ID: 7506300
[TBL] [Abstract][Full Text] [Related]
12. Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies.
Kim M; Qiao ZS; Montefiori DC; Haynes BF; Reinherz EL; Liao HX
AIDS Res Hum Retroviruses; 2005 Jan; 21(1):58-67. PubMed ID: 15665645
[TBL] [Abstract][Full Text] [Related]
13. Methods for analysis of biologically functional antibodies to the HIV-1 gp120 principal neutralizing domain.
Devash Y; Rusche JR; Nara PL
Biotechnol Ther; 1991; 2(1-2):49-62. PubMed ID: 1845124
[TBL] [Abstract][Full Text] [Related]
14. Absence of cytotoxic antibody to human immunodeficiency virus-infected cells in humans and its induction in animals after infection or immunization with purified envelope glycoprotein gp120.
Nara PL; Robey WG; Gonda MA; Carter SG; Fischinger PJ
Proc Natl Acad Sci U S A; 1987 Jun; 84(11):3797-801. PubMed ID: 3473484
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal anti-idiotypic antibody mimicking the principal neutralization site in HIV-1 GP120 induces HIV-1 neutralizing antibodies in rabbits.
Fung MS; Sun CR; Liou RS; Gordon W; Chang NT; Chang TW; Sun NC
J Immunol; 1990 Oct; 145(7):2199-206. PubMed ID: 2398276
[TBL] [Abstract][Full Text] [Related]
16. [An enzyme-linked immunosorbent assay determining anti-principal neutralizing determinant antibodies using synthetic peptides deduced from cDNA sequences of HIV-1 V3 loop domain].
Ishimoto S; Fujimura Y; Yamanaka T; Shimoyama T; Nishida S; Matsuoka H; Nishikawa K; Yoshioka A; Narita N; Honda M
Rinsho Ketsueki; 1995 Mar; 36(3):193-9. PubMed ID: 7540222
[TBL] [Abstract][Full Text] [Related]
17. Antibody responses of chimpanzees immunized with synthetic peptides corresponding to full-length V3 hypervariable loops of HIV-1 envelope glycoproteins.
Neurath AR; Jiang S; Strick N; Kolbe H; Kieny MP; Muchmore E; Girard M
AIDS Res Hum Retroviruses; 1991 Oct; 7(10):813-23. PubMed ID: 1720628
[TBL] [Abstract][Full Text] [Related]
18. Comparative studies on neutralisation of primary HIV-1 isolates by human sera and rabbit anti-V3 peptide sera.
Lawoko AL; Johansson B; Hjalmarsson S; Christensson B; Ljungberg B; Al-Khalili L; Sjölund M; Pipkorn R; Fenyö EM; Blomberg J
J Med Virol; 1999 Oct; 59(2):169-79. PubMed ID: 10459152
[TBL] [Abstract][Full Text] [Related]
19. Antibody recognition of amino acid divergence within an HIV-1 neutralization epitope.
Goudsmit J; Zwart G; Bakker M; Smit L; Back N; Epstein L; Kuiken C; d'Amaro J; de Wolf F
Res Virol; 1989; 140(5):419-36. PubMed ID: 2479966
[TBL] [Abstract][Full Text] [Related]
20. Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides.
Palker TJ; Clark ME; Langlois AJ; Matthews TJ; Weinhold KJ; Randall RR; Bolognesi DP; Haynes BF
Proc Natl Acad Sci U S A; 1988 Mar; 85(6):1932-6. PubMed ID: 2450351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
